The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23.
José Alberto Navarro-GarcíaRafael Salguero-BodesLaura González-LafuenteLaura Martín-NunesElena Rodríguez-SánchezTeresa Bada-BoschEduardo HernándezEvangelina Mérida-HerreroManuel PragaJorge SolísFernando ArribasHéctor BuenoMakoto Kuro-OMaría Fernández-VelascoLuis Miguel RuilopeCarmen DelgadoLuis M RuilopePublished in: BMC medicine (2022)
The FGF23-Klotho axis emerges as a new therapeutic target to prevent acquired long QT syndrome in uremia by minimizing the predisposition to potentially fatal ventricular arrhythmias and sudden cardiac death in patients with CKD.